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Abstract 
Since anthracyclines were introduced in the
treatment of non-Hodgkin’s lymphoma in the
late 1960s, they have been acknowledged as a
cornerstone in the management of the disease
and, in particular, of aggressive lymphomas.
The high efficacy of anthracycline-containing
regimens must, however, be balanced against
the drug-related toxicity, which mainly affects
the cardiovascular system and represents a
major concern for clinicians, especially in the
treatment of elderly patients. Patients’ out-
comes could be further improved, particularly
for those at high risk of cardiotoxicity, by sub-
stituting liposomal doxorubicin for conven-
tional doxorubicin. This approach has already
been tested and shown to be effective in sev-
eral cancers, especially in different subsets of
patients with diffuse large B-cell lymphoma.
The use of liposomal doxorubicin in combina-
tion regimens for other conditions, such as fol-
licular lymphoma and splenic marginal zone
lymphoma, is also under investigation, and
early results are promising. 
Challenges in treating lymphoma
Non-Hodgkin’s lymphoma (NHL) is the most
common cancer of the lymphatic system and
represents the fifth most frequent cancer in
Western countries. Recent estimates of lym-
phoma incidence in Italy predict that there will
be nearly 15,000 new cases of NHL in 2011.
Diffuse large B-cell lymphoma (DLBCL) is the
most common aggressive lymphoma, repre-
senting more than 40% of new cases. Most im-
portantly, more than half of all patients with
NHL and DLBCL are older than 60 years.1-3
History of anthracycline use in NHL 
The history of treatment of aggressive NHL
started more than 50 years ago, with the use of
alkylators as single agents, with disappointing
results. In 1969, the first antitumor antibiotic
– doxorubicin – became available and, over
time, clinical trials demonstrated that this was
the most effective single agent for the treat-
ment of NHL. Subsequently, the combination
treatment of cyclophosphamide, hydroxy-
daunorubicin (doxorubicin), vincristine, and
prednisone (CHOP) was found to be a highly
effective treatment for aggressive NHL and be-
came the gold standard.4 In addition, reduction
of the inter-treatment interval,5 and the addi-
tion of rituximab to CHOP (R-CHOP)6-8 were
both found to improve patient outcomes. 
At present, the R-CHOP combination given
every 3 weeks is the standard treatment for
DLBCL in elderly patients and is associated
with a 5-year overall survival rate of about
60%.7 The transferability of R-CHOP from clin-
ical trials to practical management of elderly
patients with DLBCL is, however, still an issue.
The R-CHOP regimen is often poorly tolerated
in elderly patients, which necessitates dose re-
ductions that may result in a lower response
and cure rate compared with younger pa-
tients.9 Moreover, treatment-related mortality
for this therapy is close to 6%, and cardiologic
toxicity induced by doxorubicin remains a con-
cern for clinicians.10-12 Different strategies
have been adopted in an attempt to reduce an-
thracycline-induced toxicity. These include the
design of combination regimens with reduced
drug doses,9,13-15 a maintained anthracycline
dose but with the addition of cardioprotec-
tants,16,17 or the use of liposome-encapsulated
anthracyclines.18,19
Non-pegylated liposomal doxorubicin
(NPLD) has a shorter circulation time than its
pegylated counterpart.20 Animal data showed
that NPLD reduced drug delivery to the my-
ocardium and increased delivery to the liver,
spleen, and bone marrow.21 Significantly, this
pharmacokinetic profile is associated with re-
duced myelosuppression,19 gastrointestinal
toxicity,18 and risk of cardiotoxicity,20 when
compared with standard formulations. Inter-
estingly, research on the delivery of liposomal
formulations to different tissues also showed
that their entry into the spleen and bone
marrow could be increased if treatment was
preceded by the administration of empty lipo-
somes, which blocked delivery of ‘active lipo-
somes’ to the liver.22 This treatment technique
could perhaps be considered in order to further
improve the delivery of liposome-encapsulated
drugs to the desired targets. 
Initial results of liposomal doxorubicin replacing doxorubicinin lymphoma chemotherapy 
The effects of substitution of liposomal dox-
orubicin into CHOP have now been demon-
strated in patients with NHL. In an early study,
NPLD was substituted into CHOP (to form the
COMP combination chemotherapy) in pa-
tients with acquired immune deficiency syn-
drome (AIDS)-related NHL. The results were
promising, with a 75% complete response
(CR) rate; the results were even more impres-
sive considering that two-thirds of the pa-
tients (67%) had an intermediate to high In-
ternational Prognostic Index (IPI).23 This
COMP combination chemotherapy was also
shown to be effective in newly diagnosed ag-
gressive NHL, with a CR rate of 67.4%, al-
though, as would be expected, hematologic
toxicity was also high (95.8% grade III or IV
neutropenia).24 Pegylated liposomal doxoru-
bicin has also been substituted into R-CHOP
for the treatment of elderly patients with
DLBCL, and produced a CR rate of 59%.25
Liposomal doxorubicin in the R-COMP combination in patients at risk of cardiotoxicity
As liposomal doxorubicin is associated with
lower cardiotoxicity, this treatment could be
considered for patients who might not be able
to receive conventional doxorubicin because
they are at risk of cardiac disease. Rigacci et
al. conducted a prospective study of R-COMP
therapy in patients at risk of cardiotoxicity be-
cause they had concurrent cardiac diseases or
had been pretreated with anthracyclines.26
There was a CR rate of 76% and an overall re-
sponse rate of 90%. Only one patient developed
an acute grade III cardiotoxicity. 
A larger, prospective European study, in-
volving several centers in Italy, Germany,
Spain, and the UK (the EUR018 trial), was
conducted to investigate the efficacy of R-
COMP in elderly patients with aggressive
lymphoma. Patients were aged at least 61
years, and some were more than 80 years old
– the median age was 72 years.27 More than
half of the patients (56%) had an IPI of 3 or
more, the median baseline left ventricular
ejection fraction (LVEF) was 61%, and the
dose intensity of NPLD was 85.3%. In the in-
Hematology Reports 2011; volume 3(s3):e4
Correspondence: Dr Stefano Luminari, Dipar -
timento di Oncologia, Ematologia e Malattie
Apparato Respiratorio, COM - Centro Oncologico
Modenese, via del Pozzo 71, 41124 Modena, Italy.
Tel. +39.059.422.5861 - Fax: +39.059.422.3707.
E-mail: sluminari@unimore.it
Key words: non-Hodgkin’s lymphoma, treatment,
anthracycline.
Conflict of interest: MF has received honoraria
from Cephalon; SL and AM report no conflicts of
interest.
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright S. Luminari et al., 2011
Licensee PAGEPress, Italy
Hematology Reports 2011; 3(s3):e4
doi:10.4081/hr.2011.s3.e4
tention-to-treat (ITT) population, the com-
plete remission rate was 57%, and this in-
creased to 66% in the population that re-
ceived at least three cycles of treatment (ef-
ficacy population). Overall survival in the ITT
population was 72%, the failure-free survival,
which takes into account those patients who
left the study prematurely, was 40%, and pro-
gression-free survival was around 70%
(Figure 1). These results were somewhat
better in the efficacy population (77%, 46%,
and 74%, respectively). Importantly, no sig-
nificant reduction in cardiac function and no
change in LVEF were apparent during treat-
ment (Figure 2), and the R-COMP regimen
was not associated with any increase in
acute cardiac toxicity. 
There are now studies of R-COMP ongoing
in patients with DLBCL who have cardiopathy
(the HEART01 trial, NCT01009970), and to
compare the cardiotoxicity of R-CHOP and R-
COMP (the NHL-14 trial, NCT00575406). 
Use of liposomal doxorubicin inother treatment combinations 
Possible next steps in treatment develop-
ment may be the substitution of liposomal dox-
orubicin into the combination of rituximab, cy-
clophosphamide, epirubicin, vinblastine, and
prednisone (R-miniCEOP). This combination
has been investigated in the ANZINTER3 trial
(NCT01148446). Preliminary results showed
that most patients older than 72 years with an
age-adjusted (aa)IPI of 0 or 1 could be treated
effectively with R-miniCEOP.15 There may be a
place for NPLD in this type of combination, in
an attempt to provide even better efficacy and
further reduce the cardiotoxicity of therapy in
this low-risk population. Use of anthracyclines in follicularlymphoma 
A retrospective analysis was conducted on
633 patients with follicular lymphoma (FL)
who received anthracycline-containing treat-
ment regimens and 128 patients who did not
receive anthracyclines. This analysis showed
longer overall survival (Figure 3) and failure-
free survival in patients who received anthra-
cyclines, compared with those who did not.28
Support for this result from a prospective, ran-
domized, controlled trial is now needed, and
recruitment has just finished for the FOLL05
study (NCT00774826) comparing rituximab,
cyclophosphamide, vincristine, and pred-
nisone (R-CVP) with R-CHOP and rituximab,
fludarabine, and mitoxantrone (R-FM) in 534
Figure 1. Kaplan-Meier analysis of the probability of (A) overall survival, (B) failure-free survival, and (C) progression-free survival in
elderly patients receiving rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisone (R-COMP)
chemotherapy for diffuse large B-cell lymphoma (results from the EUR018 trial).27 From Luminari S et al. Nonpegylated liposomal dox-
orubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results
from the phase II EUR018 trial. Ann Oncol 2010;21:1492-9. Reprinted with permission from Oxford University Press. 
Figure 2. Left ventricular ejec-
tion fraction (LVEF) from base-
line to end of treatment in elder-
ly patients receiving rituximab,
cyclophosphamide, non-pegylat-
ed liposomal doxorubicin, vin-
cristine, and prednisone (R-
COMP) chemothe rapy for dif-
fuse large B-cell lymphoma
(results from the EUR018
trial).27 From Luminari S et al.
Nonpegylated liposomal dox-
orubicin (MyocetTM) combina-
tion (R-COMP) chemo therapy
in elderly patients with diffuse
large B-cell lymphoma
(DLBCL): results from the phase
II EUR018 trial. Ann Oncol
2010;21:1492-9. Reprinted with
permission from Oxford
University Press. 
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patients with stage II-IV newly diagnosed FL. If
this study demonstrates that R-CHOP is more
effective than R-CVP and R-FM, a next step
could be to substitute a less cardiotoxic lipo-
somal doxorubicin for conventional doxoru-
bicin in this combination. 
Use of liposomal doxorubicin insplenic marginal zone lymphoma 
As it has been demonstrated that liposomal
doxorubicin is concentrated in the spleen,
this may be an excellent therapy for patients
with indolent B-cell lymphomas in this organ.
The recently completed R-COMP05 trial is a
Phase II study of R-COMP in the treatment of
splenic marginal zone B-cell lymphoma. All
patients received three courses of R-COMP,
and those who responded to this treatment
were offered three additional courses. A total
of 63 patients were enrolled, two of whom
were excluded before centralized review, and
the diagnosis was confirmed for 51 patients –
a centralized review is essential in these
sorts of studies, as the risk of misdiagnosis is
high. Preliminary results of the study indi-
cated promising outcomes with R-COMP
therapy in this group of patients.29
Conclusions 
Anthracyclines, particularly doxorubicin,
have a long-standing and important role in the
management of NHL. The CHOP and subse-
quently R-CHOP regimens are standard
therapy for this condition. More recently, the
substitution of NPLD into this treatment reg-
imen, to form R-COMP, has allowed the treat-
ment of patients who could not previously re-
ceive R-CHOP because they had already re-
ceived anthracycline therapy or were at risk of
cardiotoxicity. In addition, the use of liposomal
doxorubicin in other lymphomas, such as FL
and splenic marginal zone lymphoma, is cur-
rently under investigation and showing prom-
ising results. Using liposomal doxorubicin,
therefore, it seems likely that in the future it
should be possible to treat more and a greater
variety of patients with curative intent than in
the past. How such treatments will compare to
bendamustine is unknown.
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